Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine

AIDS Research and Human Retroviruses

Volumn 16, Issue 14, 2000, Pages 1337-1344

  Albrecht, M A ^a   Hughes, M D ^b   Liou, S H ^b   Katzenstein, D A ^c   Murphy, R ^d   Balfour, H H ^e   Para, M F ^f   Valdez, H ^g   Hammer, S M ^h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL DISEASE; MYCOBACTERIOSIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; WASTING SYNDROME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 0034692593     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050140883     Document Type: Article

References (28)

1. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
2. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
3. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
4. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
5. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy
6. Advances in antiretroviral therapy and viral load monitoring
7. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4+ cells per millimeter
8. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients
9. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: A review of North American (NUCA 3001) and European (NUCB 3001) trials
10. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection
11. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients
12. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
13. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3' thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
14. High level resistance to (-) enantiometric 2'-deoxy-3'-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase
15. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC)
16. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
17. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus ZDV plus 3TC in previously untreated patients
18. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become coresistant to zidovudine in vivo
19. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
20. Antiretroviral therapy for HIV infection in 1998
21. Safety and efficacy of abacavir (1592, ABC) with ZDV/3TC in antiretroviral naive subjects
22. Ziagen (Abacavir, ABC, 1592) combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral therapy-naive subjects (CAN 3003)
23. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) in naive adults at 24 weeks (CNA 3005)
24. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretro-viral therapy
25. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL
26. Improved survival among HIV-infected individuals following the initiation of antiretroviral therapy